Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI5752 in Subjects With Advanced Solid Tumors

Trial Profile

A Phase 1, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI5752 in Subjects With Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 18 Feb 2019

At a glance

  • Drugs Carboplatin (Primary) ; MEDI 5752 (Primary) ; Pemetrexed (Primary) ; Durvalumab; Pembrolizumab
  • Indications Solid tumours
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors MedImmune
  • Most Recent Events

    • 08 Feb 2019 Planned End Date changed from 27 Mar 2023 to 16 Feb 2023.
    • 08 Feb 2019 Planned primary completion date changed from 27 Mar 2023 to 16 Feb 2023.
    • 31 Oct 2018 Planned End Date changed from 7 Feb 2023 to 27 Mar 2023.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top